Insmed/$INSM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Insmed
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Ticker
$INSM
Sector
Primary listing
Employees
1,664
Headquarters
Website
Insmed Metrics
BasicAdvanced
$32B
-
-$6.42
1.17
-
Price and volume
Market cap
$32B
Beta
1.17
52-week high
$212.75
52-week low
$60.40
Average daily volume
2.4M
Financial strength
Current ratio
3.827
Quick ratio
3.35
Long term debt to equity
99.695
Total debt to equity
101.429
Interest coverage (TTM)
-11.87%
Profitability
EBITDA (TTM)
-980.464
Gross margin (TTM)
79.73%
Net profit margin (TTM)
-210.54%
Operating margin (TTM)
-164.04%
Effective tax rate (TTM)
-0.40%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
-28.99%
Return on equity (TTM)
-249.28%
Valuation
Price to revenue (TTM)
49.187
Price to book
43.46
Price to tangible book (TTM)
60.79
Price to free cash flow (TTM)
-30.828
Free cash flow yield (TTM)
-3.24%
Free cash flow per share (TTM)
-4.862
Growth
Revenue change (TTM)
66.73%
Earnings per share change (TTM)
15.25%
3-year revenue growth (CAGR)
35.20%
3-year earnings per share growth (CAGR)
17.94%
10-year earnings per share growth (CAGR)
12.26%
What the Analysts think about Insmed
Analyst ratings (Buy, Hold, Sell) for Insmed stock.
Insmed Financial Performance
Revenues and expenses
Insmed Earnings Performance
Company profitability
Insmed News
AllArticlesVideos
Insmed CEO Will Lewis talks its rare disease drug pipeline
CNBC Television·2 months ago
Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances
Benzinga·2 months ago
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Insmed stock?
Insmed (INSM) has a market cap of $32B as of March 05, 2026.
What is the P/E ratio for Insmed stock?
The price to earnings (P/E) ratio for Insmed (INSM) stock is 0 as of March 05, 2026.
Does Insmed stock pay dividends?
No, Insmed (INSM) stock does not pay dividends to its shareholders as of March 05, 2026.
When is the next Insmed dividend payment date?
Insmed (INSM) stock does not pay dividends to its shareholders.
What is the beta indicator for Insmed?
Insmed (INSM) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.